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Objective: This study aims to analyze the relationship of programmed cell death 1 (PDCD1)
gene polymorphism (PD1.3G/A – rs11568821) with features of systemic lupus erythematosus
(SLE) and rheumatoid arthritis (RA) in a Southern Brazilian population.
Methods: Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP)
was  performed in 95 SLE and 87 RA patients and 128 control group individuals from Santa
Catarina, Southern Brazil. The Hardy–Weinberg equilibrium (HWE) test, and odds ratio (OR)
were  analyzed, considering CI 95% and p ≤ 0.05.
Results: The PD1.3A allele frequencies were 0.095 (SLE), 0.115 (RA) and 0.078 (controls). The
genotypes of the control group were in HWE, while those of SLE and RA patients were
not.  However, we found no association between PD1.3 polymorphism and the SLE or RA
susceptibility, nor clinical or epidemiological data.
Conclusion: There was no signiﬁcant association between PD1.3 polymorphism and SLE or
RA  susceptibility in this Southern Brazilian population.
©  2015 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Associac¸ão  entre  o  polimorﬁsmo  do  gene  PDCD1  e  a  susceptibilidade  ao
lúpus  eritematoso  sistêmico  e  à  artrite  reumatoide
r  e  s  u  m  oalavras-chave:
rtrite reumatoide
úpus eritematoso sistêmico
Objetivo: Este estudo teve como objetivo analisar a relac¸ão entre o polimorﬁsmo do gene
PDCD1 (Programmed cell death 1) (PD1.3G/A – rs11568821) com caraterísticas do lúpus
eritematoso sistêmico (LES) e da artrite reumatoide (AR) em uma  populac¸ão do sul do Brasil.
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icenses/by-nc-nd/4.0/).
484  r e v b r a s r e u m a t o l . 2 0 1 6;5 6(6):483–489
Autoimunidade
Gene PDCD1
Polimorﬁsmo PD1.3
Métodos: A técnica de PCR-RFLP (Polymerase Chain Reaction-Restriction Fragment Lenght Poly-
morphism)  foi utilizada para analisar amostras de 95 pacientes com LES e 87 com AR e 128
indivíduos do grupo controle de Santa Catarina, sul do Brasil. Foi analisada a probabili-
dade de equilíbrio de Hardy–Weinberg (EHW) e o odds ratio (OR), considerando um IC 95% e
p  ≤ 0.05.
Resultados: As frequências alélicas PD1.3A foram de 0,095 (LES), 0,115 (AR) e 0,078 (controles).
Os  genótipos do grupo controle estavam em EHW, enquanto aqueles dos pacientes com LES e
AR  não estavam. No entanto, não foi encontrada nenhuma associac¸ão entre o polimorﬁsmo
PD1.3 e a susceptibilidade ao LES ou à AR, nem com dados clínicos ou epidemiológicos.
Conclusão: Não foi encontrada associac¸ão signiﬁcativa entre o polimorﬁsmo PD1.3 e a sus-
ceptibilidade ao LES ou à AR nesta populac¸ão do sul do Brasil.
©  2015 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CCIntroduction
Autoimmune rheumatic diseases share clinical ﬁndings and
are caused by multiple factors including a complex genetic
basis coupled with non-genetic factors, which contribute in
different degrees for each affected individual.1 Genetic poly-
morphisms of the human genome have been investigated and
new evidence of genetic contribution to rheumatic diseases
has been discovered. Among autoimmune diseases, systemic
lupus erythematosus (SLE) and rheumatoid arthritis (RA), have
been the main targets of genetic variation studies, once they
represent multisystem disorders with a wide spectrum of clin-
ical manifestations.1,2
SLE affects mainly women of reproductive age, and its
major characteristic is the production of autoantibodies
against nuclear antigens, as double stranded DNA (dsDNA),
ribonucleoproteins (RNP) and Smith (Sm) antigen; as well as
cytoplasmic, and cell-surface antigens.3 These autoantibodies
deposit on several organs causing inﬂammation and leading
to symptoms that could range from subtle to life-threatening.
Constitutional manifestations including fever, fatigue and
weight loss may occur, as well as joint pain due to arthritis,
malar and discoid rashes, photosensitivity, and involvement
of the central and peripheral nervous system, kidneys, heart
and lungs.1 Progression of the disease is individual and het-
erogeneous, so different biomarkers have been sought in order
to unveil disease susceptibility and development as well as to
guide therapeutic decisions.4,5
RA pathogenesis is complex and results in chronic
inﬂammation of joints and, in many  patients, systemic
complications, such as subcutaneous nodules, pulmonary
involvement and early atherosclerosis, that may be challeng-
ing regarding treatment.6 In order to come to better prognosis
and outcomes in RA, the development of biomarkers that
allow disease sub-categorization are needed.7 So far, serologic
factors such as rheumatoid factor (RF) and anti-citrullinated
protein autoantibodies (ACPA); and the acute inﬂammation
marker C-reactive protein (CRP), have helped classifying RA
clinical phenotypes.8–11 Rheumatoid factor is an autoantibody
directed against the Fc portion of IgG, and correlates with
the severity of the disease12; whereas the ACPA are directed
against citrullinated proteins, and can also help to predict a
more severe and erosive disease.13BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Although the etiology of SLE and RA are not well
established, it is hypothesized that deregulated lymphocyte
activation play an important role in the breakdown of immune
tolerance, leading to autoreactivity.2,14 Involved in this pro-
cesses, co-stimulatory molecules are critical for the balance
between T cell activation and inhibition.15 Among those, the
programmed cell death 1 (PD-1) is shown to be an important
molecule involved in profound loss of self-tolerance leading
to rapid lethality associated with lymphocyte inﬁltration in
many  organs.16 This protein is expressed on the surface of
T, B and myeloid cells, and is a member of the CD28 family
that belongs to the immunoglobulin superfamily and acts as
an inhibitory molecule on T cells, after interacting with its
ligands PDL-1 and PDL-2 (programmed cell death 1 ligand 1
and 2).17 After initial activation of T cell interactions, PD-1-
PD-L may limit autoreactive T cell proliferation and cytokine
production, whereas stimulated by antigens the PD-1 damp-
ens T cell receptor (TCR) signaling. The amount of expression
of PD-1 and the degree of involvement between this protein
and its ligands regulate the threshold of T cell activation and
the amount of cytokines produced.18,19 PD-1-deﬁcient mice
develop spontaneous autoimmune diseases, indicating an
essential function of PD-1 in the mechanisms of tolerance.20–23
PD-1 is encoded by the PDCD1 gene, located at 2q37.3
locus. Among the SNPs found within this region, the PD1.3G/A
(rs11568821) potentially represents a functional polymor-
phism associated with the transcriptional regulation of
PD-1.24 The PD1.3A allele alters the binding site of RUNX1 (or
AML1) transcription factor, located on the intron 4 enhancer
region, which could lead to aberrant protein expression, sug-
gesting a mechanism for the self-tolerance breakdown.25,26
Association studies correlated the presence of the allele
PD1.3A with SLE in Mexican and Scandinavian populations,25
and with diabetes mellitus 1 and RA in Denmark and Swe-
den respectively.26,27 However, some populations in Asia are
non-polymorphic for this genomic region, presenting only the
PD1.3G allele,28–30 which emphasizes the diversity of allelic
frequency among populations, and supports the necessity to
study the association of this PDCD1 polymorphism in other
localities. In Brazil, three studies have evaluated the frequen-
cies of PD1.3 polymorphism. One in patients with pemphigus
foliaceus (also an autoimmune disease),31 in silica-exposed
workers,32 and in a cohort of patients with Chagas disease,33
demonstrating the presence of both alleles in this population.
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Table 1 – Characteristics of systemic lupus
erythematosus (SLE) and rheumatoid arthritis (RA)
patients and controls from Southern Brazil.
SLE
patients n
RA
patients n
Controls n
Female (%) 92 (96.84) 75 (86.21) 123 (96.09)
Mean age (SD) 37,35 (±12,16) 54.42 (±13.33) 47,38 (±15.04)
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Less than half of RA patients (46.15%) presented high levelSD, standard deviation.
ence, through this study we intended to evaluate the
requency of PD1.3 polymorphism in a Southern Brazilian pop-
lation and its relationship to SLE and RA susceptibility.
ethods
ltogether, 95 SLE patients, 87 RA patients and 128 control sub-
ects participated on this study, which was approved by the
ommittee on Ethics of the Federal University of Santa Cata-
ina (UFSC) (CEP/UFSC – case number 172/06), after informed
onsent was obtained from all patients and controls subjects.
omen made up 96.84% of SLE patients, 86.10% of RA patients
nd 96.09% of controls. The mean age of SLE patients was
7.35 ± 12.16 years, of RA patients was 54.42 ± 13.33 years and
f control group was 47.38 ± 15.04 years (Table 1). Patients
ere admitted at the Hospital Universitário Professor Poly-
oro Ernani de São Thiago, Florianópolis, Brazil, from 2007 to
009, and diagnosed according to the 1987 American College
f Rheumatology criteria. The control group was composed
f healthy volunteers without personal or family history of
utoimmune diseases. Familial, epidemiological and clinical
ata from individuals were obtained by questionnaires and
edical records. Regarding clinical data, we evaluated SLE
atient’s medical chart records of arthritis, photo-sensibility,
aynaud’s phenomenon, and nephritis, which were the recur-
ent clinical manifestation in this group. For RA patients, we
onsidered rheumatoid factor (RF) positivity (>20 IU/ml), and
evels of C-reactive protein (CRP) above the reference value
>5 mg/l) as the laboratorial manifestations to be associated
ith the alleles.
Whole blood samples were obtained from SLE and RA
atients and from control subjects. The DNA was extracted
Table 2 – Allele and genotype frequencies of PD1.3 polymorphis
rheumatoid arthritis (RA) patients and controls. Hardy–Weinber
and association analysis between the diseases and the PD1.3 (G
control subjects of the Brazilian population were  calculated.
SLE p value 
n = 95 
Allele G 0.905 (Ref.) 
Allele A 0.095 0.661 
GG 0.842 (Ref.) 
GA 0.126 0.940 
AA 0.032 0.755 
HWE (p value) 2(1) = 6.60 (0.010) 
2 (chi-square value), p < 0.05 was not considered in HWE. 6;5 6(6):483–489 485
using the phenol–chloroform technique.34 The PD1.3A (PDCD1)
allele was detected by polymerase chain reaction restriction
fragment length polymorphism (PCR-RFLP).35 The PCR prod-
uct of 180 bp was digested by PstI  restriction endonuclease
(BioLabs Inc., New England), according to the manufacturer
instructions. All experiments were performed with negative
and positive internal controls previously genotyped at Labo-
ratório de Genética Molecular Humana – UFPR. The product of
digestion was stained with GelRed® solution and subjected to
electrophoresis on a 3% agarose gel. DNA was visualized with
a photographed gel documentation system (MiniBISPro DNR).
The genotype was classiﬁed according to the size of the gen-
erated fragments (GG – 180 bp; GA – 180 bp, 150 bp and 30 bp;
AA – 150 bp and 30 bp).
Hardy–Weinberg equilibrium (HWE) was tested using the
2 test. Allele and genotype frequencies were estimated by
direct counting. Allele and genotype frequencies were com-
pared between patients and controls by Fisher exact test using
SPSS (version 20.0; SPSS Inc., Chicago, IL), which was also used
to calculate the odds ratio (OR) in order to determine the asso-
ciation of the PD1.3A allele and the studied diseases, as well
as its association to poor prognosis factors of SLE and RA
patients. A p value of 0.05 was adopted as the limit of sig-
niﬁcance for all tests.
Results
The allele and genotype frequencies of PD1.3 polymorphisms
found among the groups are shown in Table 2. The geno-
type distribution in the control group was in HWE  (2(1) = 2.24,
p = 0.13), but the distributions observed in SLE and RA patients
were not (2(1) = 6.60, p = 0.01 for SLE and 2(1) = 9.02, p < 0.001
for RA). Nevertheless, no association was found regarding the
alleles or genotypes and both diseases (p > 0.05) (Table 2).
Among SLE patients, 49.5% had arthritis, 40.0% complained
of photosensitivity, 15.8% experienced the Raynaud’s phe-
nomenon and 30.5% presented renal impairment. Association
between these clinical factors and PD1.3 alleles and genotypes
were analyzed, but no signiﬁcant results were found (Table 3).of CRP, and 66.67% had RF positivity. However, those factors
were not associated with the presence of PD1.3A allele either
in homozygosis or heterozygosis (Table 3).
m observed in systemic lupus erythematosus (SLE) and
g equilibrium (HWE) values for genotypic distribution,
/A) polymorphism in samples of patients and unaffected
RA p value Controls n = 128
n = 87
0.885 (Ref.) 0.922
0.115 0.364 0.078
0.816 (Ref.) 0.859
0.138 0.715 0.125
0.046 0.206 0.016
2(1) = 9.02 (<0.001) 2(1) = 2.24 (0.130)
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Table 3 – Clinical features present in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients, and
their association to PD1.3 polymorphism.
Affected SLE patients n (%) Associated p value
Allele (A) AA AA + AG
Arthritis 47 (49.5) 0.963 0.553 0.752
Photosensitivity 38 (40) 0.312 0.361 0.294
Raynaud’s phenomenon 14 (15.8) 0.570 0.827 0.777
Renal impairment 29 (30.5) 0.786 0.440 0.388
Affected RA patients n (%) Associated p value
Allele (A) AA AA + AG
RF 50 (66.67) 0.122 0.291 0.302
CRP 36 (46.15) 0.910 0.874 0.965RF, rheumatoid factor; CRP, C-reactive protein.
Discussion
For the ﬁrst time in Brazil, PDCD1 gene was considered a candi-
date for susceptibility to systemic lupus erythematosus (SLE)
and to rheumatoid arthritis (RA). Associations between the
SNP PD1.3A and clinical and laboratorial manifestations were
tested, ﬁnding no statistically signiﬁcant results.
Once genotype frequencies of SLE and RA patients were
not in Hardy–Weinberg equilibrium (Table 3), diverging from
the control group, a putative association with these diseases
was investigated. The frequency of AA genotype was very low
in all groups (0.032 in SLE, 0.046 in RA and 0.016 in controls) as
shown by other case–control studies in different populations,
where AA frequencies were all below 0.05.31,33,35–44 One Ira-
nian cohort, however, has shown AA genotype frequencies of
0.20 in controls and 0.44 in patients with Colorectal Cancer
(CCR), revealing as well, an association between this geno-
type and CCR (p = 0.0005).45 In Brazil, the frequency of the AA
genotype was also low according to three different cohorts
involving patients with Chagas disease (0.03 and 0.01 in
controls),33 pemphigus foliaceus (0.007 and 0.01 in controls),31
and reaching 0% in a group of silica-exposed workers (0.03 in
controls).32 Interestingly, some populations carry the minor
allele, but no homozygous description was found, present-
ing only GG and AG individuals. Yet, the analyzed genotypes
showed no statistically signiﬁcant OR value when considering
the risk of developing SLE or RA in our study.35,46–48
Associations of the PD1.3A allele to disease development
have been increasingly investigated, not only in SLE and
RA patients,25,26,28,29,35–37,46,49–55 but also in other autoim-
mune and chronic inﬂammatory diseases such as Diabetes
Mellitus type I (T1D),27,38,42 Graves and Addison disease,39
Ankylosing spondylitis,44 and Myasthenia Gravis,41 as well
as in other conditions as CCR,45 and silica exposed workers
(Table 4).32 The PD1.3A allele frequency highly differs among
populations worldwide, three Chinese studies related to RA
and Vogt–Koyanagi–Harada Syndrome found no allele varia-
tion in their population,28,30,55 which was also observed in
29Japan in a similar study. European studies show the pres-
ence of the PD1.3 polymorphism, yet association to diseases
varies among studies. An association of PD1.3A to SLE was
demonstrated by Prokunina et al.25,26 in European womenand Mexicans, and by Ferreiros-Vidal et al.51 in SLE patients
from Germany, Czech Republic and Hungary. Nevertheless,
Ferreiros-Vidal et al. have previously shown a reversal of
patterns in a Spanish cohort, with decreased risk of SLE devel-
opment in PD1.3A carriers.50 RA patients were also genotyped
for PDCD1 rs11568821 polymorphism by few groups,28,29,36,55
and as mentioned previously, Chinese and Japanese cohorts
carried solely the PD1.3G allele. A Swedish study was the only
one to present data on RA and rs11568821 polymorphism, but
association between the disease and allele or genotypes was
not demonstrated.36 Nonetheless, the same group showed an
association of PD1.3A and RA patients negative for RF. In the
present study we could not ﬁnd any association between RF
positivity or high levels of CRP and the alleles or genotypes
investigated.
SLE patients were also inquired about clinical manifesta-
tions as arthritis, photosensitivity, Raynaud’s phenomenon,
and renal involvement. However, we found no association
between PD1.3 alleles or genotypes and these manifesta-
tions. Thorburn et al.53 evaluated the role of four PDCD1 SNPs
(PD1.1A, PD1.3A, PD1.5T and PD1.6A) and SLE nephritis, arthri-
tis, antiphospholipid antibody (APA), and double-stranded
DNA positivity, ﬁnding no association of PD1.3A allele and its
associated haplotype and any clinical phenotype. The occur-
rence of APA in SLE patients was also analyzed by Sanghera
et al.35 unraveling a protection of PD1.3A carriers against
APA in both SLE (OR = 0.57; 95% CI: 0.32–1.01) and controls
(OR = 0.40; 95% CI: 0.19–0.82). Prokunina et al.,26 Johansson
et al.,37 and Nielsen et al.49 evaluated renal manifestations in
SLE patients. The ﬁrst and second studies showed an associa-
tion between the PD1.3A allele and renal disorders in patients
with SLE from Sweden (OR = 2.6; 95% CI: 1.4–4.8, and OR  = 2.62;
95% CI: 1.28–5.35, respectively); and the third one did not ﬁnd
an association of lupus nephropathy and the minor allele of
PD1.3. As for RA, neither RF nor CRP was associated to PD1.3A
allele presence either in homozygosis or heterozygosis, as
opposed to what was found by Prokunina et al.26
Although studies show the PD1.3 G/A polymorphism asso-
ciated with RA, SLE and other autoimmune diseases and their
clinical manifestations, our study revealed no differences in
minor allele carries between RA and SLE patients and controls
neither disease manifestations.
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Table 4 – PD1.3A (rs11568821) allele frequencies found by different studies.
Population Studied disease PD1.3A frequencies % OR (95% CI) Reference
Controls Patients
Swedish SLE 8.0 11.0 1.44 (0.93–2.23) Prokunina et al., 2002
Mexican SLE 2.0 7.0 3.23 (1.46–7.16)b Prokunina et al., 2002
Danish T1D 6.8 12.2 1.92 (1.1–3.3)b Nielsen et al., 2003
Spanish SLE 12.9 9.4 0.70 (0.54–0.90)b Ferreiros-Vidal et al., 2004
Danish SLE 6.8 11.6 1.80 (0.96–3.4) Nielsen et al., 2004
European (women) SLE 7.0 11.0 1.60 (1.17–2.18)b Prokunina et al., 2004a
Swedish RA 7.3 8.5 1.18 (0.99–1.4) Prokunina et al., 2004b
African American
(women)
SLE  10.0 5.0 2.19 (0.54–8.85) Sanghera et al., 2004
European American
(women)
SLE 11.0 13.0 1.23 (0.87–1.73) Sanghera et al., 2004
North Swedish SLE 5.6 7.3 1.35 (0.90–2.02) Johansson et al., 2005
Hong Kong Chinese RA 0 0 NA Kong et al., 2005
Finnish SLE 6.0 3.0 0.50 (0.20–1.26) Sigurdsson et al., 2005
Swedish SLE 9.0 9.0 1.00 (0.68–1.45) Sigurdsson et al., 2005
Mato Grosso do Sul –
Brazilian
Pemphigus Foliaceus 9.6 5.8 0.58 (0.33–1.03) Braun-Prado and Petzel-Erler 2007
CEUa SLE 8.1 17.1 2.35 (1.1–4.9)b Ferreiros-Vidal et al., 2007
Italiana SLE 10.7 18.7 1.92 (0.9–3.9) Ferreiros-Vidal et al., 2007
Greek SLE 10.6 12.7 1.22 (0.8–1.8) Ferreiros-Vidal et al., 2007
Japanese RA 0 0 NA Iwamoto et al., 2007
British Graves’ disease 88.4 89.7 1.13 (0.85–1.50) Sutherland et al., 2007
American SLE 4.7 7.2 1.59 (0.78–3.23) Thorburn et al., 2007
Mexican Childhood-onset SLE 2.0 5.2 2.73 (1.35–5.56) Velázquez-Cruz et al., 2007
American Primary biliary cirrhosis 11.7 12.5 1.08 (0.74–1.57) Juran et al., 2008
Swedish Autoimmune HMG 8.5 10.8 1.32 (0.74–2.35) Sakthivel et al., 2008
French CMV infection after kidney
transplantation
12.9 12.8 1.38 (0.90–2.11) Hoffmann et al., 2009
Han Chinese Vogt–Koyanagi–Harada
syndrome
0  0 NA Meng et al., 2009
Caucasian Polish T1D 12.9 13.5 1.05 (0.71–1.55) Fichna et al., 2010
Iranian Ankylosing spondylitis 11.2 9.3 0.81 (0.48–1.34) Soleimanifar et al., 2010
Mexican Hypersensitivity pneumonitis 3.8 6.1 1.65 (0.59–4.75) Zún˜iga et al., 2010
Caucasian Polish Chronic urticaria 10.0 10.0 0.97 (0.51–1.86) Brzoza et al., 2012
Brazilian Silica-exposed workers 13.3 4.3 0.29 (0.10–0.88)b Rocha et al., 2012
African American SLE 2.0 2.6 1.31 (0.94–1.81) Sanchez et al., 2012
Brazilian Chagas disease 10.0 9.0 0.90 (0.61–1.33) Dias et al., 2013
German Liver transplant recipients 12.5 10.0 0.78 (0.46–1.33) Thude et al., 2013
Iranian Colorectal cancer 40.5 60.6 2.27 (1.50–3.44)b Youseﬁ et al., 2013
Han Chinese RA 0 0 NA Liu et al., 2014
OR, odds ratio; CI, conﬁdence interval; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; T1D, type 1 diabetes; NA, not available;
HMG, human myasthenia gravis.
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